<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573596</url>
  </required_header>
  <id_info>
    <org_study_id>DASTOP2</org_study_id>
    <nct_id>NCT03573596</nct_id>
  </id_info>
  <brief_title>Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment</brief_title>
  <acronym>DASTOP2</acronym>
  <official_title>Persistence Of Major Molecular Remission In Chronic Myeloid Leukemia After A Second Stop Of Tki Treatment In Patients Who Failed An Initial Stop Attempt: A Multicenter Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll CML patients who have failed a first TKI stopping attempt. After
      failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment
      for another 2 years. If MR4 or better is re-achieved and maintained for at least one year,
      patients will be eligible for a second stop. After verification of MR4, TKI treatment will be
      stopped and patients followed in the same manner as after first stop. If MMR is lost (BCR-ABL
      &gt;0.1% (IS)), TKI treatment will once again be restarted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DASTOP2 study aims to retreat patients who relapse in the Euro-SKI study (or who stopped
      TKI treatment outside trials but according to EURO-SKI procedures), with TKI for at least
      another 3 years, out of last two years with dasatinib. If MR4 or better is re-achieved and
      maintained for at least one year, patients will be eligible for a second stop. After
      verification of MR4, TKI treatment will be stopped and patients followed in the same manner
      as after first stop. If MMR is lost (BCR-ABL &gt;0.1% (IS)), TKI treatment will once again be
      restarted.

      Patients exhibiting hematological relapse after first stop attempt will not be offered a
      second stop within this study. The same applies to patients in whom TKI was restarted
      prematurely (without loss of MMR).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 2, multicenter study, prospective, open label, uncontrolled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>successful MMR maintenance</measure>
    <time_frame>one year</time_frame>
    <description>The proportion of patients maintaining MMR at 12 months after discontinuing TKI a second time (survival without loss of major molecular response, MMR, defined as BCR-ABL1 &gt; 0.1% on IS at one time point).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlates with succesful stop</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of clinical and biological factors correlating with persistence of MMR or better after second TKI stop.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reachievement of MR4</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who re-achieved stable MR4, and were offered study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reachievement of MR4</measure>
    <time_frame>1 year</time_frame>
    <description>Time to reachievement of MR4 after second loss of MMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events after TKI withdrawal</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events related to second TKI stop, clinical and biological factors correlated to development of these AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TKI restart without prior molecular relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Occurrence of a restart of TKI without prior molecular relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>CML, Relapsed</condition>
  <arm_group>
    <arm_group_label>dasatinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.</description>
    <arm_group_label>dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CML in chronical phase (CP) under TKI treatment after failing a prior attempt to stop
             treatment within EURO-SKI or outside the study but according to EURO-SKI trial
             procedures. For the latter group this requires at least 3 years of TKI treatment
             (first line or second line due to intolerance to first line) before first stop, and
             MR4 for at least one year before stopping.

          2. Treated with TKI for at least one year after having failed a prior attempt to stop
             TKI. Previous TKI can be any.

          3. Typical BCR/ABL1 transcript (b3a2 and/or b2a2) must have been confirmed at diagnosis
             or later during the disease course.

          4. 18 years or older.

        Exclusion Criteria:

          1. Previous hematological relapse after first stop of TKI.

          2. Previous AP/BC at any time in the history of the disease.

          3. Restart of TKI without loss of MMR after first stop

          4. Current participation in another clinical study.

          5. Previous or planned allogeneic stem cell transplantation.

          6. Patients with contra-indications to dasatinib therapy due to comorbidities.

          7. Subjects with acute hepatitis B virus (HBV) infections.

          8. Uncontrolled or significant cardiovascular disease.

          9. Pulmonary arterial hypertension.

         10. Pleural or pericardial effusions of any grade at study entry are excluded

         11. History of significant bleeding disorder unrelated to CML

         12. Hypersensitivity to dasatinib and excipients of dasatinib tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Olsson-Strömberg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Uppsala University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulla Olsson-Strömberg, MD PhD</last_name>
    <phone>+46 (0) 18-611 00 00</phone>
    <email>ulla.stromberg@talk21.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeroen JW Janssen, MD PhD</last_name>
    <phone>+31204442230</phone>
    <email>jjwm.janssen@vumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Stentoft, MD PhD</last_name>
      <phone>+45 78 45 00 00</phone>
      <email>jespsten@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreja Dimitrijevic, MD PhD</last_name>
      <phone>+45 66 11 33 33</phone>
      <email>Andreja.Dimitrijevic@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satu Mustjoki, MD PhD</last_name>
      <phone>+358-9-47171898</phone>
    </contact>
    <contact_backup>
      <last_name>Perttu Koskenvesa, MD PhD</last_name>
      <email>perttu.koskenvesa@helsinki.fi</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lydia Roy, MD PhD</last_name>
      <phone>+33 1 49 81 21 11</phone>
      <email>lydia.roy@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Wolf, MD PhD</last_name>
      <phone>+49 228 2870</phone>
      <email>dominik.wolf@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU University medical center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeroen JW Janssen, MD PhD</last_name>
      <phone>+31204442230</phone>
      <email>jjwm.janssen@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Gert J Ossenkoppele, MD PhD</last_name>
      <phone>+31204442230</phone>
      <email>g.ossenkoppele@vumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter E Westerweel, MD PhD</last_name>
      <phone>+3178654 11 11</phone>
      <email>p.e.westerweel@asz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Blijlevens, MD PhD</last_name>
      <phone>+3124366 82 06</phone>
      <email>Nicole.Blijlevens@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University medical center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter AW te Boekhorst, MD PhD</last_name>
      <phone>+3110 703 49 11</phone>
      <email>p.teboekhorst@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland, Bergen University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Tore Gjertsen, MD PhD</last_name>
      <phone>+47 55 97 50 00</phone>
      <email>bjorn.gjertsen@uib.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Gedde Dahl, MD PhD</last_name>
      <phone>+47 915 02770</phone>
      <email>tobias.gedde-dahl@rikshospitalet.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waleed Majeed, MD PhD</last_name>
      <phone>+47 51 51 80 00</phone>
      <email>waleed.majeed.mohammed@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tromsø University Hospital</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Vik, MD PhD</last_name>
      <phone>+47 77 62 60 00</phone>
      <email>anders.vik@uit.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital-Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Hjorth Hansen, MD PhD</last_name>
      <phone>+47 72 57 30 00</phone>
      <email>henrik.hjorth-hansen@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kourosh Lofti, MD PhD</last_name>
      <phone>+46 10 103 00 00</phone>
      <email>Kourosh.Lotfi@regionostergotland.se</email>
    </contact>
    <contact_backup>
      <last_name>Arta Dreimane, MDPhD</last_name>
      <email>Arta.Dreimane@regionostergotland.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunderby Sjukhus</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneli Enblom-Larsson, MD PhD</last_name>
      <phone>+46 920 28 20 00</phone>
      <email>anneli.enblom-larsson@nll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Richter, MD PhD</last_name>
      <phone>+46 46 17 10 00</phone>
      <email>johan.richter@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leif Stenke, MD PhD</last_name>
      <phone>+46 8 517 700 00</phone>
      <email>leif.stenke@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Lotta Ohm, MD PhD</last_name>
      <email>lotta.ohm@swipnet.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berit Markevärn, MD PhD</last_name>
      <phone>+46 90 785 00 00</phone>
      <email>berit.markevarn@vll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital (Akademiska)</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Olsson-Strömberg, MD PhD</last_name>
      <phone>+46 (0) 18-611 00 00</phone>
      <email>ulla.stromberg@talk21.com</email>
    </contact>
    <contact_backup>
      <last_name>Stina Söderlund, MD PhD</last_name>
      <email>stina.soderlund@akademiska.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Björeman, MD PhD</last_name>
      <phone>+46 19 602 10 00</phone>
      <email>mats.bjoreman@regionorebrolan.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>J.J.W.M. Janssen</investigator_full_name>
    <investigator_title>Clinical Hematologist, Deputy Chief of Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>second stop</keyword>
  <keyword>dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study results will be published as soon as possible. Steering committee will decide on sharing IPD. This is still pending.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

